KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)
Phase 2 Recruiting
130 enrolled
MK-3475-G21
Phase 1/2 Recruiting
20 enrolled
Phase II Study of Pembrolizumab in Combination With Lenvatinib in Patients With TNBC, NSCLC, and Other Tumor Types and Brain Metastases
Phase 2 Recruiting
104 enrolled
A Study of ASP3082 in Adults With Advanced Solid Tumors
Phase 1 Recruiting
681 enrolled
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).
Phase 1 Recruiting
500 enrolled
A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)
Phase 1 Recruiting
250 enrolled
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
361 enrolled
LUCERNA
Phase 3 Recruiting
500 enrolled
Pan Tumor Rollover Study
Phase 2 Recruiting
1,500 enrolled
MINUTE
Phase 4 Recruiting
776 enrolled
SUNRAY-01
Phase 3 Recruiting
1,264 enrolled
KEYNOTE-E12
Phase 1 Recruiting
78 enrolled
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Phase 1 Recruiting
290 enrolled
I-SPY
Phase 2 Recruiting
5,000 enrolled
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Phase 1/2 Recruiting
616 enrolled
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Phase 3 Recruiting
750 enrolled
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
Phase 1/2 Recruiting
37 enrolled
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
Phase 1 Recruiting
240 enrolled
EBNK-ST-001
Phase 1/2 Recruiting
83 enrolled
A Study of YL242 in Subjects With Advanced Solid Tumors
Phase 1/2 Recruiting
424 enrolled
Evaluation of RBS2418 in Subjects With Advanced, Metastatic Solid Tumors
Phase 1 Recruiting
164 enrolled
PanTumor-101
Phase 1 Recruiting
590 enrolled
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
Phase 1 Recruiting
130 enrolled
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
Phase 1 Recruiting
56 enrolled
BOREALIS-1
Phase 1 Recruiting
200 enrolled
KYANITE-1
Phase 1/2 Recruiting
250 enrolled
A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
Phase 1/2 Recruiting
137 enrolled
AURORAS-1
Phase 1 Recruiting
200 enrolled
PANCARDINAL-2
Phase 2 Recruiting
24 enrolled
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
Phase 1 Recruiting
90 enrolled
ABILITY-1
Phase 1/2 Recruiting
115 enrolled
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
Phase 1/2 Recruiting
365 enrolled
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Phase 1/2 Recruiting
316 enrolled
Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma
Phase 2 Recruiting
37 enrolled
DRUP
Phase 2 Recruiting
1,550 enrolled
HYPERION
Phase 2 Recruiting
128 enrolled
Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer
Phase 2 Recruiting
24 enrolled
A Study in Patients With Advanced Cancers
Phase 1/2 Recruiting
332 enrolled